{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:20:42Z","timestamp":1783642842951,"version":"3.55.0"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to one third of patients with chronic migraine suffer from daily headache, these individuals have hardly been studied. We conducted a prospective cohort study, including patients with chronic migraine and treated with OnabotulinumtoxinA according to the PREEMPT paradigm. The primary endpoint was to assess whether patients with chronic migraine and daily headache had a different response after three sessions of OnabotulinutoxinA than patients without daily headache. The secondary endpoint was to analyse the presence of predictive factors that could be associated with a higher response to OnabotulinumtoxinA. Patients with daily headache had a reduction of 14.9 (SD: 9.7) headache days per month, patients with 22\u201329 headache days a reduction of 10.6 (SD: 9.9) days, and patients with 15\u201321 headache days a reduction of 8.6 (SD: 7.1) days (p &lt; 0.001). In the univariate regression analysis, a higher number of headache days per month at baseline was associated with higher odds of reduction in the number of headache days per month after OnabotulinumtoxinaA treatment (OR: 0.474, 95% CI: 0.278\u20130.670, p &lt; 0.001). This association was maintained in the multivariate regression analysis (OR: 0.540, 95% CI: 0.333\u20130.746, p &lt; 0.001). In our sample, daily headache was not associated with a worse response to OnabotulinumtoxinA treatment. A higher frequency of headache at baseline was a predictor of better response to OnabotulinumtoxinA treatment.<\/jats:p>","DOI":"10.3390\/toxins13060432","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T22:40:37Z","timestamp":1624315237000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-9862","authenticated-orcid":false,"given":"Enrique","family":"Mart\u00ednez-P\u00edas","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid, 47003 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-6002","authenticated-orcid":false,"given":"\u00c1ngel L.","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid, 47003 Valladolid, Spain"},{"name":"Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Department of Medicine, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-6064","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Sierra","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid, 47003 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Trigo","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid, 47003 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid, 47003 Valladolid, Spain"},{"name":"Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"ref_1","unstructured":"(2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1526-4610.2003.03068.x","article-title":"Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine","volume":"43","author":"Bigal","year":"2003","journal-title":"Headache"},{"key":"ref_3","first-page":"973","article-title":"Preventive Migraine Treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"ref_4","unstructured":"Ezpeleta, D., and Pozo-Rosich, P. (2015). Gu\u00edas Diagn\u00f3sticas y Terap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda. Gu\u00eda Oficial de Pr\u00e1ctica Cl\u00ednica en Cefaleas, Editorial Luzan 5."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_8","first-page":"408","article-title":"Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice","volume":"34","author":"Cuadrado","year":"2019","journal-title":"Neurologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11916-005-0067-7","article-title":"Chronic daily headache in the absence of medication overuse: Is daily or continuous pain more treatment-resistant than chronic daily headache with pain-free days?","volume":"9","author":"Lake","year":"2005","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_11","first-page":"133","article-title":"Chronic migraine with daily headache. Literature review","volume":"72","author":"Sierra","year":"2021","journal-title":"Rev. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11916-018-0733-1","article-title":"What Are We Missing in the Diagnostic Criteria for Migraine?","volume":"22","author":"Tinsley","year":"2018","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0035-1571215","article-title":"The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems","volume":"36","author":"Kumar","year":"2016","journal-title":"Semin. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/PRS.0000000000004795","article-title":"Surgical treatment of migraine headache: Back to the future","volume":"142","author":"Gfrerer","year":"2018","journal-title":"Plast Reconstr. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.12999","article-title":"Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies","volume":"57","author":"Aurora","year":"2017","journal-title":"Headache"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ornello, R., Ahmed, F., Negro, A., Miscio, A.M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., and Brunelli, N. (2021). Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain Ther., in press.","DOI":"10.1007\/s40122-021-00253-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: The REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K","volume":"15","author":"Khalil","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-019-0971-6","article-title":"Real world preventative drug management of migraine among Spanish neurologists","volume":"20","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3389\/fneur.2018.00808","article-title":"OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine with Medication Overuse","volume":"9","author":"Caronna","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s10194-018-0953-0","article-title":"Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: Results from the COMPEL Study","volume":"20","author":"Young","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gaul, C., Br\u00f6mstrup, J., Fritsche, G., Diener, H.C., and Katsarava, Z. (2011). Evaluating integrated headache care: A one-year follow-up observational study in patients treated at the Essen headache centre. BMC Neurol., 11.","DOI":"10.1186\/1471-2377-11-124"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1526-4610.2007.00807.x","article-title":"Prognostic significance of personality profiles in patients with chronic migraine","volume":"47","author":"Luconi","year":"2007","journal-title":"Headache"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/head.13765","article-title":"Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study","volume":"60","author":"Alpuente","year":"2020","journal-title":"Headache"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee, Olesen, J., Bousser, M.G., Diener, H.C., Dodick, D., First, M., Goadsby, P.J., G\u00f6bel, H., Lainez, M.J., and Lance, J.W. (2006). New appendix criteria open for a broader concept of chronic migraine. Cephalalgia, 26, 742\u2013746.","DOI":"10.1111\/j.1468-2982.2006.01172.x"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 33, 629\u2013808.","DOI":"10.1177\/0333102413485658"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s40064-015-0957-z","article-title":"OnabotulinumtoxinA treatment for chronic migraine: Experience in 52 patients treated with the PREEMPT paradigm","volume":"4","author":"Pedraza","year":"2015","journal-title":"Springerplus"},{"key":"ref_39","unstructured":"Santos, S., and Pozo-Rosich, P. (2020). Manual de Pr\u00e1ctica Cl\u00ednica en Cefaleas. Recomendaciones Diagn\u00f3stico-Terap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda, Editorial Luzan 5."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: Predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Santos","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1526-4610.2005.05067.x","article-title":"Duration of migraine is a predictor for response to botulinum toxin type A","volume":"45","author":"Eross","year":"2005","journal-title":"Headache"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-020-01113-6","article-title":"Sustained response to onabotulinumtoxin A in patients with chronic migraine: Real-life data","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fneur.2019.00678","article-title":"Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment","volume":"10","author":"Caratozzolo","year":"2019","journal-title":"Front. Neurol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/6\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:20:32Z","timestamp":1760163632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/6\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["toxins13060432"],"URL":"https:\/\/doi.org\/10.3390\/toxins13060432","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}